Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFα, improves health-related quality of life in patients with moderate to severe Crohn’s disease

BACKGROUND AND AIMS: Certolizumab pegol, a polyethylene glycolated Fc-free Fab’ was efficacious and well tolerated in patients with moderate-to-severe Crohn’s disease in a previously reported randomized, placebo-controlled study. In this paper, we report the effect of certolizumab pegol on health-re...

Descripción completa

Detalles Bibliográficos
Autores principales: Rutgeerts, Paul, Schreiber, Stefan, Feagan, Brian, Keininger, Dorothy L., O’Neil, Liz, Fedorak, Richard N.
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2007
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2225995/
https://www.ncbi.nlm.nih.gov/pubmed/18071721
http://dx.doi.org/10.1007/s00384-007-0395-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2225995/
https://www.ncbi.nlm.nih.gov/pubmed/18071721
http://dx.doi.org/10.1007/s00384-007-0395-7

Ejemplares similares